Cyxone

The European patent office announced that the patent application will be granted as a unitary patent as of November 1^st, 2023, and will be valid in the countries that have ratified the UPC (Unitary Patent Court) agreement – at the moment 17 out of 39 member states of the European Patent Office’s cooperation.

The intention to grant communication is an official announcement from the patent office indicating that the patent application has reached the stage where the patent is about to be approved. When approved, the patent will be valid until 2032.

“Receiving this announcement from the EPO is very valuable. We chose this novel track with the T20K patent, and we are pioneering the new UPC system that came into force the June 1^st, 2023. The intention of the UPC is to significantly expediate the patent process resulting in a faster procedure and reduced costs, which is very valuable for the innovation process. The ambition with the UPC is to enable patent protection in 25 EU member states with a single patent application. This is yet another important milestone in progressing the T20K project forward and we are pleased to receive this announcement which future-proofs the T20K development program,” says Carl-Magnus Högerkorp, CEO at Cyxone.

Contact

Carl-Magnus Högerkorp, CEO
Tel: +46 (0)70 781 88 12
Email: carl.hogerkorp@cyxone.com

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com